Tech Company Financing Transactions
Tacalyx Funding Round
Tacalyx closed a $13 million Seed funding round on 4/29/2026. Investors included Boehringer Ingelheim Venture Fund, Creathor Venture and Eurazeo.
Transaction Overview
Company Name
Announced On
4/29/2026
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to see TCX-201, an antibody drug conjugate (ADC) against an undisclosed TACA, through preclinical development while advancing the its broader pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Magnusstr. 11
Berlin, 12489
Germany
Berlin, 12489
Germany
Phone
Website
Email Address
Overview
Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz. We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Engela
Chief Financial Officer
Kajo Wiest
Chief Scientific Officer
Peter Sondermann
Browse more venture capital transactions:
Prev: 4/29/2026: TrialClinIQ venture capital transaction
Next: 4/29/2026: AIDoc Medical venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs